Patents by Inventor Michael Braunagel

Michael Braunagel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phagemid for antibody screening
    Patent number: 6730483
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 4, 2004
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Phagemid for antibody screening
    Publication number: 20020160463
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Application
    Filed: April 8, 2002
    Publication date: October 31, 2002
    Applicant: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Phagemid for antibody screening
    Patent number: 6387627
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: May 14, 2002
    Assignee: Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dübel, Michael Braunagel, Iris Klewinghaus
  • Phagemid library for antibody screening
    Patent number: 6127132
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: October 3, 2000
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Phagemid for antibody screening
    Patent number: 5985588
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: November 16, 1999
    Assignee: Deutsches Krebsforschungszentrum Stiftung des offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus
  • Phagemid for antibody screening
    Patent number: 5849500
    Abstract: A phagemid has been constructed that expresses an antibody fused to coliphage pIII protein. The phagemid is suitable for selecting specific antibodies from large gene libraries with small quantities of antigen. The antibody-pIII gene can be strongly repressed, so that it allows antibody libraries to be amplified without the danger of deletion mutants predominating. After induction, large quantities of the fusion protein may be expressed.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: December 15, 1998
    Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
    Inventors: Frank Breitling, Melvyn Little, Stefan Dubel, Michael Braunagel, Iris Klewinghaus